T. Rowe Price Investment Management’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $45.4M | Buy |
+3,246,934
| New | +$45.4M | 0.03% | 406 |
|
|
2024
Q2 | – | Sell |
-498,969
| Closed | -$10.2M | – | 630 |
|
|
2024
Q1 | $10.2M | Hold |
498,969
| – | – | 0.01% | 540 |
|
|
2023
Q4 | $10.7M | Sell |
498,969
-148,044
| -23% | -$3.18M | 0.01% | 511 |
|
|
2023
Q3 | $13.3M | Hold |
647,013
| – | – | 0.01% | 509 |
|
|
2023
Q2 | $19.1M | Hold |
647,013
| – | – | 0.01% | 482 |
|
|
2023
Q1 | $14.9M | Buy |
647,013
+13,655
| +2% | +$315K | 0.01% | 493 |
|
|
2022
Q4 | $17.6M | Buy |
633,358
+211,001
| +50% | +$5.87M | 0.01% | 472 |
|
|
2022
Q3 | $13M | Buy |
+422,357
| New | +$13M | 0.01% | 484 |
|